TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05207215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
Study: NCT02688400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Study: NCT01546961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2.
Study: NCT02688400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03045432

Intervention type: OTHER
Group type: OTHER
Intervention: oral-teaching
Description: The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral-teaching
Description: The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.

Intervention type: OTHER
Group type: OTHER
Intervention: regular rehabilitation program
Description: Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular rehabilitation program
Description: Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
Study: NCT00917163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supralimus(R) Sirolimus-Eluting Coronary Stent System
Description: Drug eluting stent implantation in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V™ Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation in the treatment of coronary artery disease
Study: NCT00002558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT03605433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
Study: NCT05080062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Requirements and functional Schedule
Description: An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: a pain rehabilitation-program
Study: NCT03577860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 4 mL
Description: The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 15 mL
Description: The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
Study: NCT00548730

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
Study: NCT02344446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skilled Therapy
Description: Active physical therapy treatment
Study: NCT01359670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
Study: NCT00760539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
Study: NCT04218448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnorelaxation
Description: Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development
Study: NCT03262610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: daily subcutaneous injection
Study: NCT04111250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
Study: NCT00716092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (linagliptin)
Description: once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (linagliptin)
Description: once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sitagliptin)
Description: once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5mg once daily for 28 days
Study: NCT04606277

Intervention type: OTHER
Intervention: Smartphone addiction scale, physical activity scale and depression questionnaire
Description: Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
Study: NCT03802864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bupivacaine
Description: After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
Study: NCT03496519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Durvalumab and Trabectedin
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion of Durvalumab and Trabectedin
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
Study: NCT03627884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Catheter Lock Solution
Description: Using Sodium Bicarbonate Catheter Lock Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Catheter Lock Solution
Description: Using Sodium Bicarbonate Catheter Lock Solution
Study: NCT01509781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of suction drain(s) following mastectomy
Description: One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive skin sutures.
Description: Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
Study: NCT02370433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Neostigmine and Glycopyrrolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Neostigmine and Glycopyrrolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Neostigmine and Glycopyrrolate
Study: NCT00846105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid MRSA PCR test for screening carriers
Description: In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid MRSA PCR test for screening carriers
Description: In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
Study: NCT00801801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Sorafenib
Description: Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
Study: NCT02230956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injection into the intra-articular space of the study knee.
Study: NCT04413292

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers
Study: NCT04111250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
Study: NCT04413292

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers
Study: NCT00307749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 20mg, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 40mg, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 80mg, once daily for 24 weeks
Study: NCT01843998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.1% Ointment
Description: Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
Study: NCT01078480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation using a precontoured titanium plate and screws
Description: Operation using a precontoured titanium plate and screws

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Displaced midshaft fracture of the collar bone
Description: Displaced midshaft fracture of the collar bone treated with an arm sling
Study: NCT03164980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectidin (Yondelis)
Description: To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectidin (Yondelis)
Description: To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
Study: NCT00929162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 Zibotentan
Description: 10 mg oral tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 IV on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 IV on day 1 every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for ZD4054 10 mg
Study: NCT00213655

Intervention type: BIOLOGICAL
Intervention: bladder tumor recurrence
Description: bladder tumor recurrence assessed by clinical and biological exams

Intervention type: BIOLOGICAL
Intervention: bladder tumor recurrence
Description: bladder tumor recurrence assessed by clinical and biological exams
Study: NCT03738202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention package
Description: Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan
Study: NCT04352478

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathological result
Description: Incidental gallbladder cancer and other pathology

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathological result
Description: Incidental gallbladder cancer and other pathology
Study: NCT01893385

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D (drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D (drug)
Study: NCT00868465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine
Description: Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
Study: NCT03945539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
Study: NCT01217476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study: NCT03945539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.